SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below a major psychological level have dominated discussion, with traders pointing to leveraged-position liquidations as adding to the pressure. The community is split between expectations of further downside amid risk-off and rate concerns and calls to buy an oversold dip.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas is drawing attention as its Phase 3 REGAL trial of GPS reaches final analysis after the 80th event, with topline results expected in November. Traders celebrated an after-hours jump and speculated about a data leak or short covering, while skeptics stressed that the results are still unknown and managements positive language does not establish success.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about business disruption and concern that the incident could damage trust. Traders debated whether it was a technical failure or a cyberattack, though hacking claims remained speculation, and many questioned why the shares held up amid the disruption.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs confirmed decision to remove Strategy from its indexes is raising concerns about passive-fund selling and pressure on the stock, while Bitcoins decline is adding to the weakness. Traders disagree on whether the index impact is already priced in, with bearish forced-selling concerns countered by dip-buying and hopes for a rebound.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention after a sharp selloff tied to a Q3 revenue miss and the lack of detailed guidance, with traders debating cash burn, possible dilution, and managements communication. Optimism about the BCG-naive trial results, a planned FDA filing, expanded Anktiva access, and sepsis studies is countered by concern that commercial growth may not keep pace with expectations.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

A broad crypto selloff has XRP sliding toward key support, with traders pointing to Bitcoin-led market weakness, inflation and rate-hike concerns, and leveraged liquidations. The community is split between holders accumulating the dip and bearish traders warning of more downside, while some also cite Ripple-related token supply and fading regulatory hopes.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

FDA discussions over assay refinement pushed Candels planned prostate-cancer BLA filing to mid-2027, and traders are also concerned about potential dilution. The community is split between viewing this as a manufacturing and regulatory delay rather than a setback to the clinical data, and questioning managements credibility and execution.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,212,724.47747979. The last known price of Ethereum is 2,011.23339821 USD and is down -2.26 over the last 24 hours. It is currently trading on 14326 active market(s) with $10,433,558,649.69 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp crypto-market selloff, with traders pointing to inflation and hawkish rate expectations, Bitcoin weakness, and leveraged-position liquidations as pressure on prices. The community is divided between bearish calls for further losses and buyers treating the decline as an oversold opportunity, while key support levels are closely watched.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs departure as CEO amid reports of a personal scandal has sparked concern about Nvidias leadership transition, with Colette Kress serving as interim CEO. Traders are divided between fears that the company may struggle without Huang and views that its business can withstand the change, with some buying the selloff ahead of earnings.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoins sharp decline and broader weakness in crypto-linked stocks are weighing on Coinbase, with traders focused on its repeated lows and whether the selloff will continue. The discussion is predominantly bearish, though some see the stock as oversold or holding support and expect a rebound if crypto stabilizes.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare ConferencePR NewswireSAN DIEGO, Nov. 10, 2026 SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced...

NBIX or GRDN: Which Is the Better Value Stock Right Now?

NBIX vs. GRDN: Which Stock Is the Better Value Option?

Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid Choice 

Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.

All You Need to Know About Neurocrine (NBIX) Rating Upgrade to Buy

Neurocrine (NBIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 25.5% in Neurocrine (NBIX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA (valbenazine) Capsules

Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA (valbenazine) Capsules Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA (valbenazine) CapsulesPR...

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress

Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall CongressPR NewswireSAN DIEGO, Nov. 3, 2026 SAN DIEGO, Nov. 3...

NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View

Neurocrine Biosciences beats Q3 earnings and revenue estimates as strong Ingrezza demand, Crenessity growth and higher 2026 sales guidance drive momentum.

Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of +29.53% and +8.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of $3.29 up 51.61% YoY
• Reported revenue of $1.12B up 41.24% YoY

Neurocrine Biosciences' earnings were below prior-year figures with an equity-investment loss; VYKAT XR has a potential FDA safety signal under evaluation, and four customers represent over 90% of gross product sales.

Neurocrine Biosciences' Q3 INGREZZA sales increased alongside record new prescriptions; the Soleno acquisition added VYKAT XR, while Phase 2 studies initiated in Alzheimers cognition, schizophrenia, and pediatric CAH.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Neurocrine Biosciences gained VYKAT XR through its $2.9-billion acquisition of Soleno Therapeutics, completed in May.</li><li>FPWR noted seven reported deaths and more than 100 reports of serious adverse events involving heart or breathing issues in patients taking the drug.</li><li>In August 2025, short-seller Scorpion Capital published a lengthy report alleging serious risks of fluid buildup, pulmonary edema, and heart failure with Vykat XR use, along with concerns about clinical-trial data.</li></ul><p>Shares of Neurocrine Biosciences closed 3% lower on Wednesday and further slipped 1% after-hours after the Foundation for Prader-Willi Research (FPWR) recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on its drug VYKAT XR for fluid retention and related heart or breathing problems.</p><p>FPWR blog from Monday outlines practical steps for real-world use of the drug, the first FDA-approved treatment for extreme hunger (hyperphagia) in PWS patients aged four and older. FPWR further advises families to review the full prescribing information and consult PWS specialists so the potential benefits of reduced hyperphagia can be weighed carefully against the risks.</p><p>Since Vykat XR’s March 2025 launch, more than 800 people have received prescriptions. The medicine can help control appetite but may cause edema that, in some cases, has been linked to serious complications, according to experts.</p><h2 class="st-heading-2">Heightened Focus On Safety Signals</h2><p>FPWR noted seven reported deaths and more than 100 reports of serious adverse events involving heart or breathing issues in patients taking the drug. Many of those individuals already had obesity, multiple medications, or untreated sleep apnea. The foundation stresses that PWS itself carries elevated baseline risks, so a direct link is not always clear. Still, it recommends safety tests before starting treatment, ongoing checks for swelling or breathing changes, and care from physicians experienced with the syndrome.</p><h2 class="st-heading-2">Neurocrine Adds Vykat XR</h2><p>Neurocrine Biosciences gained VYKAT XR through its $2.9 billion acquisition of Soleno Therapeutics, completed in May. Soleno developed and launched the once-daily pill.</p><p>While still under Soleno, the drug faced scrutiny. In August 2025, short-seller Scorpion Capital published a lengthy report alleging serious risks of fluid buildup, pulmonary edema, and heart failure, along with concerns about clinical-trial data. The following month, Soleno disclosed the death of a 17-year-old patient who had been taking the medicine, though the company and treating physician assessed the death as unrelated to the drug. Investor lawsuits later claimed Soleno had downplayed fluid-retention signals.</p><h2 class="st-heading-2">Broader Impact On PWS Pipeline</h2><p>Safety worries have slowed other PWS programs. Aardvark Therapeutics paused its late-stage trial of ARD-101 last year after cardiac observations in healthy volunteers, and the FDA later placed a clinical hold. Years earlier, Zafgen ended development of beloranib after patient deaths linked to blood clots. Acadia Pharmaceuticals also discontinued its candidate after a failed efficacy study.</p><h2 class="st-heading-2">How Did NBIX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around NBIX stayed within ‘bearish’ territory while message volume stayed at ‘normal’ levels.</p><p>A Stocktwits user highlighted that no clear link has been established between the drug’s use and the negative side effects.</p><p><stembedurl>https://www.stocktwits.com/GoIrish1776/message/661644013</stembedurl></p><p>“I always thought vykat/soleno was a bad drug and investment,” another user wrote.</p><p><stembedurl>https://www.stocktwits.com/outlawinvestor1/message/661718610</stembedurl></p><p><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://stocktwits.comhttps://stocktwits.com/symbol/NBIX/symbol/NBIX">NBIX stock</a> has gained 10% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-cars-facing-more-demand-than-stock-buyers-face-extended-waits-for-base-model-3-model-y-and-cybertruck/cZo8SNZRJWH">Tesla Cars Facing More Demand Than Stock? Buyers Face Extended Waits For Base Model 3, Model Y And Cybertruck</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Neurocrine Biosciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems.

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Safety Warnings

The Foundation for Prader-Willi Research has recommended that doctors treating people with Prader-Willi syndrome (PWS) should closely track patients on VYKAT XR for fluid retention and related heart or breathing problems. 


American Century ETF Trust - Avantis U.S. Equity ETF

JPMorgan Active Growth ETF

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Feed

News

Sentiment

Earnings

Fundamentals

Info

NBIX News